As an industrial platform under the Group which is specialized in clinical transfer of biomedicine and stem cell technology, it works on development of stem cell technology as well as clinical research and application of immune cell technology. The “Beike Biotechnology National Biomedicine Big Data Industry Park” invested by YUANZON Biology, based upon its continuous R&D innovation capability in the fields of individualized medicine including cell technology and genetic engineering, has built general stem cell bank cluster, clinical biotherapy transfer research platform, and international advanced health management center which integrates medical testing and serious disease screening, prevention and treatment. Meanwhile, YUANZON Biology has invested hundreds of new drug research institutes and teams all over the world.
YUANZON-Beike Sichuan General Cell Bank
YUANZON-Beike Sichuan General Cell Bank is located in Pioneering Medical Center in Chengdu Hi-tech Zone, and its first phase covers an area of nearly 6400 m2. The Bank contains regional general cell preparation center, general cell testing platform, general cell quality management platform, life science research laboratory, general life science exhibition hall and cellular medicine anti-aging exploration center, and will have a large cytologic science exhibition hall.
What's more, the Cell Bank has also introduced most advanced profound hypothermia storage system, cryogenic centrifugal system, real-time thermostatic equipment monitoring system, automatic isolation system of umbilical cord blood, microscopy imaging system, etc., and a series of high-end imported equipment. The main cell preparation area will be built in strict accordance with “B+A” cleanliness class specified by GMP. Allowing for such aspects as overall construction scale, cleanliness class, research level and quality system, the benchmarking program will be a superb cell technology platform in Southwest China upon completion of the program, which will represent the highest standard in cell industry in Southwest China.
In the mean time, the construction of Beike National Biomedicine Big Data Industry Park, which covers second phase of Sichuan General Cell Bank, has been commenced in Zhonghe Area, Chengdu Hi-tech Zone in August 2018. The Park is provided with total investment of nearly 2 billion yuan, covering area of 44,000m2 and overall floorage of nearly 200,000m2, and will be put into operation in 2022.
Furthermore, YUANZON-BEIKE owns Keyannuo Biotechnology, a high-end medical cosmetology brand, and also Keyannuo Medical Cosmetology Clinic, both of which are expanding on the strength of stem cell medical cosmetology and will support YUANZON-BEIKE General Cell Bank.
In the future, the general cell bank cluster all over Asia together with the Group's another industrial complex program -- Sino Japanese International Healthy Care Precinct will provide research base and cell preparation and storage services for lift health industry of the whole race by following the new cell industry development model of “storage+preparation+R&D”.
National Biomedicine Big Data Industry Park
In order to promote the rapid development of biomedicine industry, the Group has invested in construction of National Biomedicine Big Data Industry Park program in Chengdu Hi-tech Zone. Provided with total investment of 2 billion yuan and covering area of 44,000m2, the Group establishes Beike Biotechnology west headquarter to coordinate settlement, R&D, sale and all other businesses among relevant enterprises in West China. The establishment also covers regional cell center and general cell bank, first domestic individualized cell technology CRO/CMO base, cell testing center, cytotherapy testing platform, 3rd-party medical examination testing platform, international advanced cytotherapy research-oriented hospital, healthcare industry incubation center, international life health convention&exchange center, and national and provincial biomedicine industry platform.
